Drug Approval | October 21, 2025
FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Subscribe To Our Newsletter & Stay Updated
